Amicus Therapeutics Hits New 52-Week High of $14.43

Amicus Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 14.43 on March 20, 2026. This achievement marks a notable increase from its 52-week low of USD 5.51, reflecting a robust performance over the past year. The stock has demonstrated a remarkable 43.58% increase in value, significantly outperforming the S&P 500, which has seen a gain of 14.9% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology industry, Amicus Therapeutics holds a market capitalization of USD 4,512 million. Despite being loss-making, the company continues to navigate its financial landscape with a debt-to-equity ratio of 0.59. The price-to-book ratio stands at 19.58, indicating the market's valuation of the company's assets relative to its stock price. This recent high underscores the company's position within the market and highlights the ongoing trends in its performance metrics.